Michele Martin

2006 Research Trainee Award,

T cell therapy of breast cancer: defining and circumventing barriers to T cell infiltration of the tumour microenvironment

T cells are white blood cells involved in a variety of our immune system responses, including detection and destruction of cancer cells. With T cell therapy, “tumour-reactive” T cells are isolated from a patient’s blood, and large numbers are grown outside the body. These T cells are then infused back into the patient to help the body recognize and destroy cancer cells, a method called adoptive immunotherapy.

Michele Martin is studying the potential for using T cell therapy to treat breast cancer. Early results show about 19 per cent of tumours will regress or shrink with this treatment – unprecedented with other types of treatment – while the rest have partial or no regression. Michele is investigating how some of the tumours manage to exclude the T cells and also whether combining T cell therapy with low doses of chemotherapy can facilitate T cell infiltration into these tumours. If successful, this approach could improve breast cancer cure rates and reduce the side effects associated with current treatments.

Completed award term, March 2008

Back to 2006 Research Trainee Awards

 

Research Details

Research Area
Biomedical

University/Institution
University of Victoria

Research Location
BC Cancer Agency (Victoria)

Faculty/Department
Science / Biology

Supervisor
Dr. Brad Nelson, Adjunct Associate Professor, Science / Biology